Oncology Meeting Resources

In this section, you can find all available abstracts, presentations and webcasts on OncologyPRO.

Here below, you can search across all meeting resources by session title, presentation title, presenter or keyword. Results can then be refined by topic, event and publication date.

The use of these presentations is for personal educational purposes only.
ESMO thanks the authors for their generosity.




Format available

http://oncologypro.esmo.org/Meeting-Resourc...ncology-Singapore-November-2017/Glioblastoma

Date: 22 Jan 2018
Presenter: M. Preusser, AT
Resources: Presentation, Webcast
Topics: Cancer Immunology and Immunotherapy, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...d-Cancers/Precision-medicine-in-brain-tumors

Date: 08 Jan 2018
Presenter: R. Soffietti, IT
Resources: Presentation, Webcast
Topic: Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...id-Cancers/Gliomas-state-of-the-art-approach

Date: 08 Jan 2018
Presenter: M. van den Bent, NL
Resources: Webcast
Topic: Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...-Lymphoma-Lugano-November-2017/CNS-Lymphoma2

Date: 13 Dec 2017
Presenter: M. Ghielmini, CH
Resources: Presentation
Topics: Haematologic Malignancies, Lymphomas, Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...e-South-African-expanded-access-program.-20P

BackgroundIpilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of patients with advanced pretreated melanoma.

Date: 08 Dec 2017
Presenter: Bernardo Rapoport
Resources: Abstract
Topic: Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...elanoma-patients-treated-with-Ipilimumab-33P

BackgroundThe checkpoint inhibitor Ipilimumab induces long-lasting clinical responses in a proportion of patients with metastatic melanoma. However, most patients do not benefit from therapy.

Date: 08 Dec 2017
Presenter: Christina Jensen
Resources: Abstract
Topic: Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...-for-dendritic-cell-based-tumor-vaccines-50P

BackgroundTumor vaccines are a specific modality of cancer immunotherapy. They are based on the administration to a cancer patient of tumor antigens (TAs) or dendritic cells (DCs) previously pulsed with known TAs.

Date: 08 Dec 2017
Presenter: Mario Leonardo Squadrito
Resources: Abstract
Topics: Central Nervous System Malignancies, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...lignant-melanoma-treated-with-ipilimumab-73P

BackgroundCheckpoint inhibitors including the CTLA-4 blocking antibody ipilimumab have become the new standard therapy of many metastatic cancers. Development of anti-drug antibodies (ADAs) after...

Date: 08 Dec 2017
Presenter: Anders Kverneland
Resources: Abstract
Topic: Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...ection-hormone-resistant-prostate-cancer-78P

BackgroundSome tumor molecules circulate in the blood, and in some cases, they are used as markers of the disease (CEA, PSA). Several authors have reported the efficacy of some of these molecules for...

Date: 08 Dec 2017
Presenter: Eduardo Lasalvia-Prisco
Resources: Abstract
Topics: Biomarkers, Cancer in Special Situations, Central Nervous System Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...F-mutated-metastatic-melanoma-patients-98TiP

BackgroundAdoptive T-cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has proven to be a powerful treatment option for patients with metastatic melanoma with response rates of approximately...

Date: 08 Dec 2017
Presenter: Troels Borch
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Biomarkers, Central Nervous System Malignancies